# The Gift of the OMERACT Filter

Jasvinder Singh, MD, MPH
University of Alabama at Birmingham
Birmingham Veterans Affairs Medical Center
Mayo Clinic College of Medicine
On Behalf of the OMERACT Steering Committee

Sincere thanks to Maarten Boers, MSC, MD, PhD at VU University Medical Center Amsterdam, Netherlands for slides

### Outline

- What is a core set and why do we need them?
  - Issues with Trials
- Current initiatives to develop core sets
  - Outcome Measures in Rheumatology (OMERACT)
  - Core Outcome Measures in Effectiveness Trials (COMET)
- Existing definitions, conceptual structures and their history
- OMERACT proposal for core areas of measurement

### Problems with trials

- Trials are done to evaluate
   whether an intervention is effective and safe
- Choice of measures to reflect benefit and harm
- In most areas choices not standardized
  - heterogeneity between trials
  - potential for bias (selective outcome reporting)
  - choice of measures less relevant to users

### Solution

### Development of trial core sets

- Minimum set of outcomes that should be measured and reported in all clinical trials of a specific condition
- What is an outcome?
- How to decide what belongs in a core set?

# "Outcome ME asures in R heumatoid A rthritis C linical Trials"

### Outcome Measures in Rheumatology\*

- Informal, unofficial
- Group of health professionals and patient experts interested in outcome measures and endpoints in rheumatology

<sup>\*</sup> www.omeract.org

## Rheumatology, 1980-1990 No consensus over which measures to include in RA trials

- >25 different measures available
- 5 meetings: no single consensus
  - Confusion: purpose, focus of measurement, and selection of measures
  - Increasing recognition of the importance of sensitivity to change
  - Transatlantic divide

### OMERACT 1 Maastricht, 1992

- Core set for RA trials
- Minimum relevant improvement patients/trials
- Composite measures/ improvement criteria

### WHO/ILAR core set RA clinical trials

- global assessments patient & assessor
- pain
- painful joint count
- swollen joint count
- physical disability
- acute phase protein
- in studies ≥ 1 year: X-rays hands & feet

### OMERACT 11 (Pinehurst, 2012)

#### preconference symposium

- CAT/IRT
- mini-module
- Psoriatic Arthritis
- workshops
- Worker Productivity
- Acute Gout
- Ultrasound responsiveness RA
- Vasculitis
- OMERACT Filter 2.0
  - Truth: Areas/Domains
  - Truth: Instruments
  - Discrimination & Feasibility
  - Putting it all together
    - Patient Reported Outcomes
    - Imaging & Biomarkers

#### extra activities

- Fellow trainingextended interest group
- Flares in RA special interest groups
- Myositis
- MRI-Juvenile Infl. Arthritis
- PROMIS
- Hand Osteoarthritis
- Equity
- Polymyalgia Rheumatica
- MRI-inflammatory arthritis
- Item Response Theory
- Hip Osteoarthritis
- Connective Tissue Disease/ Interst. Lung disease

### **Bottom line**

Achieving consensus over measures involves:

- Content
  - Education in methodology
  - Agreeing on:
    - Purpose
    - Domain(s)
    - Applicability of specific measures
  - Iteration

### Bottom line

Achieving consensus over measures involves:

- Content
- Process
  - Data-driven
  - Iterative, stepwise
  - Inclusivity
    - Important role for dissenters
    - Harsh data softened by political considerations

### OMERACT Filter to select measures

To be applicable in its intended setting, a measure must be

- truthful
- discriminative
- feasible

### Truth

- free from bias
  - criterion, construct validity
- relevant
  - content, face validity

### Discrimination

- able to distinguish between states that are of interest:
  - at one time point
  - at different time points
  - reliability, reproducibility, sensitivity to change

Feasibility

- time
- costs
- interpretability

- Filter works best to select instruments once the areas of measurement have been decided on
- Truth: "...measure what it's supposed to..." but how to decide on the supposition?
- in what areas we need to decide core areas of measurement

# Example WHO/ILAR core set rheumatoid arthritis clinical trials


- global assessments by patient & assessor
- pain
- painful joint count
- swollen joint count
- physical disability
- acute phase protein
- in studies ≥ 1 year: X-rays hands & feet

### RA core set & outcome

- Outcome:
  - "how a patient feels, functions or survives"
  - patient global
  - pain
  - physical function
- Disease activity
  - assessor global
  - swollen and tender joint counts
  - acute phase protein
- Damage: X-rays

### Patient input in OMERACT started in 2002

- Core set is deficient because it does not include enough (patient-important) outcome measures
  - Fatigue
  - Sleep Quality
- ...Content validity problem!
- ...Core area problem!
- To decide on core sets,
   we need to define core areas first



### Core areas of measurement

- Def.: areas that should always be addressed by measures included in a core set for trials aimed at a specific health condition
- to decide on core areas, we need:
  - a conceptual structure of health and health conditions
  - consensus on which areas in this structure are core
  - consensus on whether core areas are generic or specific to a certain health condition

### Definitions


- health
- health intervention
- core area: aspect of a health condition that needs to be measured to appropriately assess the effects of a health intervention.
- (sub)domain: component of core area: a concept to be measured, a further specification of an aspect of health, categorized within a core area.

### Definitions

- health
- health intervention
- core area: essential aspect of a health condition...
- (sub)domain: construct within a core area
- outcome: any identified result in a (sub)domain arising from exposure to a causal factor or a health intervention.
- measurement instrument: a tool to measure a quality or quantity of a variable.

### Existing conceptual structures and their history

- WHO 2001
  International Classification of Functioning (ICF)
  - universal classification of human functionality, both positive and negative





contextual factors (environmental; personal)


Concepts

Impact of Health Conditions


Pathophysiological Manifestations









<sup>\*</sup> in all areas, domains can be generic or made more specific:




<sup>\*</sup> in all areas, domains can be generic or made more specific:




<sup>\*</sup> in all areas, domains can be generic or made more specific:



specific for patient preference



<sup>\*</sup> in all areas, domains can be generic or made more specific:




separately to allow assessment of benefit and harm.

eg. disease-specific, time specific (eg. short or long-term), specific for patient preference

Context

<sup>\*</sup> in all areas, domains can be generic or made more specific:






agreement on what to measure at least one Domain from each Core Area


### Core Domain Set

agreement on what to measure at least one Domain from each Core Area





### Core Outcome Measurement Set

agreement on how to measure at least one applicable Instrument per Domain



agreement on how to measure at least one applicable Instrument per Domain





# Thank YOU! Questions, Comments...